secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2022-07-25T23:59:59+00:00
Accession:  0001104659-22-082470
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel files patent lawsuit against Annora to block generic TAVALISSE
--------------------------------------------------------------------

- Filed suit in U.S. District Court for New Jersey against Annora Pharma, Hetero Labs, and Hetero USA for patent infringement.
- Lawsuit responds to Annora's ANDA seeking FDA approval for a generic version of TAVALISSE (fostamatinib).
- Annora sent Paragraph IV Notice Letter in June 2022 alleging the five asserted patents are invalid or not infringed.
- Asserted patents: 7,449,458, 8,263,122, 8,652,492, 8,771,648, and 8,951,504 listed in the FDA Orange Book.
- Rigel seeks equitable relief to enjoin Annora from infringing the patents covering TAVALISSE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922082470/0001104659-22-082470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922082470/tm2221725d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-082470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer